Pharmacotherapy. Position Paper: Pharmacotherapy. Introduction. Victorian Alcohol and Drug Association (VAADA) Issued August 2011
|
|
- Walter Cornelius Perkins
- 6 years ago
- Views:
Transcription
1 Pharmacotherapy Issued August 2011 The effectiveness of pharmacotherapy 1 in reducing harm is supported by indisputable evidence including sources from the World Health Organisation (WHO). In Victoria, the pharmacotherapy system is in a severe state of disrepair and has not been supported to cater for the current burgeoning levels of need, which became evident following the heroin glut around the turn of the century and the reduced availability of heroin resulting in increased programmatic uptake. The system requires reform with an emphasis on access, workforce development, equity and costs. Introduction The Victorian pharmacotherapy system is currently in crisis and in dire need of reform. This system is based on voluntary participation from pharmacists (dispensers) and general practitioners (prescribers), with the number of dispensers and prescribers not increasing commensurately with the growing community need. Four key themes underscore the limitations of the system being: access, workforce development, equity and cost. Victorian Alcohol and Drug Association (VAADA) Position Paper: Pharmacotherapy This position paper will provide a brief overview of the Victorian pharmacotherapy system and outline areas requiring reform to ensure that harms associated with substance use are minimised. The evidence supporting the efficacy of pharmacotherapy is very strong with the program reducing significant harm to the community and enabling thousands of Victorians to experience improvements in health. A joint position paper from the World Health Organisation (WHO), the UN Office of Drugs and Crime and UNAIDS (2004:2) asserts that substitution maintenance therapy 2 is one of the most effective treatment options for opioid dependence. The position paper lists the benefits of substitution maintenance therapy (pharmacotherapy): Reduces HIV risk factors (and other blood borne viruses); Reduces heroin use; Reduces mortality; and Reduces crime (2004:2). 1 This Position Paper refers exclusively to the prescription and use of methadone, buprenorphine and the combination of buprenorphine and naloxone to meet service users physical opioid needs. 2 Substitution maintenance therapy, pharmacotherapy maintenance, opioid substitution therapy and opioid replacement therapy are some of the terms which are used to describe the treatment or maintenance of people dependent on opioids with pharmaceutical opioids. In this position paper, we will use the term pharmacotherapy unless quoting directly from another source.
2 It should be noted that methadone is an essential medicine listed by WHO (WHO 2011). Further, the Victorian Department of Health 3 (2006:8) asserts that pharmacotherapy also enhances social responsibility and productivity, as well as stabilising the patient s life and reducing chaotic drug taking. Finally, Chalmers et al (2009:ix) and Ritter and Chalmers (2009:2) note that pharmacotherapy is cost effective given the resultant savings in health, law and order and social expenses which would be accrued in its absence. Pharmacotherapy in Victoria The pharmacotherapy system was developed in Victoria in 1972 and was delivered to a small number of service users through specialist clinics (Rowe 2008:34). Up until the mid 1980s, abstinence was the overarching goal of drug treatment and it was only with a growing awareness of HIV and other blood borne viruses that harm reduction began to achieve prominence and pharmacotherapy became a major response to heroin use (Ritter and Chalmers 2009:3). Currently, specialist clinics support prescribers and dispensers, and provide secondary consultations or advice as appropriate. The current pharmacotherapy model, although suitable for the mid 1990s, has not grown commensurately with the rapidly increasing number of program participants (with service users more than doubling in the 11 years from 5,334 in 1998 to 12,576 in 2009 (Australian Institute of Health and Welfare 2010:10) to well over 13,000 as of January 2011 (McDonough 2011)). Moreover, current levels of demand impact adversely on the program which is struggling to keep up and thus there is a need to increase the capacity of specialist pharmacotherapy services to provide assistance to prescribers and dispensers. The overburdening of this program has resulted in a highly fragile and tenuous model of service delivery, with the treatment of large numbers of service users adversely impacted upon when, for instance, a participating dispenser or prescriber closes down. VAADA is of the view that the current system is under resourced and cannot cater for the huge demand and thus is unable to maintain and build on the benefits evident with this style of treatment; therefore significant reform of the system is necessary. VAADA contributed to the Victorian Pharmacotherapy Review and highlighted a number of challenges facing the system. A summary of these challenges which have been detailed in the VAADA State Budget Submission 2010/11 (2009:30 1), are as follows: a general shortage of prescribers and dispensers; a skewed distribution of those prescribers across Melbourne and rural and regional areas; costly dispensing fees for both clients and service providers; limited succession planning for existing prescribers; limited addiction medicine support; limited planning and integrated care for clients, particularly for clients with complex needs; 3 The Department of Human Services oversaw the preparation of the document, Policy for Maintenance Pharmacotherapy for Opioid Dependence; however, the Department of Health is now responsible for managing Pharmacotherapy policy. 2
3 limited specialist pharmacotherapy providers; and lack of alternative models for pharmacotherapy. These, in many cases long standing, system deficiencies facing the Victorian pharmacotherapy system can be characterised under four interrelated themes being, access, workforce development, equity and cost, which are detailed below. Access There is a need to ensure that pharmacotherapy services are available to all members of the public who require them, irrespective of locale and financial situation. The capacity of service users to participate in public life should not be impinged upon by their participation in the pharmacotherapy program. Ready and timely access to pharmacotherapy is a deciding factor for participation. Logistical and geographical factors are significant for a number of service users, especially those residing in rural and regional areas. This is made more poignant in light of the limited number of prescribers. The tyranny of distance, combined with inflexible dosing times (Ritter and Chalmers 2009:35), may be an overwhelming factor for some service users with familial and employment obligations who do not have ready access to a motor vehicle. The rising population and expansion of Melbourne s growth corridors require appropriate infrastructure to enable timely access to pharmacotherapy. This may be problematic as the voluntary system of GPs and pharmacists nominating to respectively prescribe and dispense creates a lottery for emerging communities regarding the proximity of supporting prescribers and dispensers. It should be noted that even brief gaps in service can result in the relapse and the attenuation of hard fought wins for service users. The pharmacotherapy system reform must account for rising populations and growth areas and deliver contingencies which plug gaps in service. Related to the rising population is the inertia of prescriber levels. There have been significant challenges in encouraging GPs to prescribe resulting in a small number of prescribers, some with a large number of pharmacotherapy service users. VAADA is concerned as system stability is entirely reliant on the prescribers capacity and willingness to prescribe pharmacotherapy. Thus, retirement, illness or even vacations can have a devastating effect on the stability of pharmacotherapy service users. In many cases, the system is unable to cater for such inevitable circumstances. VAADA has been informed by some AOD treatment agencies that a number of prescribers are fairly senior in years and are potential candidates for retirement, which, when it occurs, will decimate the system. Ritter and Chalmers also note this threat to the system (2009:17). Many of the challenges evident with prescribers are also evident with dispensers. The average number of pharmacotherapy service users per dispenser in Victoria has increased from 26 (2006) to 29.2 (2010) per dispenser (AIHW 2011:39). Dispensers interface, often daily, with pharmacotherapy service users. In the case of conflict between dispensers and service users or lack of payment (dispensing fees will be discussed below under equity and costs ) the service user can be refused pharmacotherapy. This can result in significant challenges for the service user to remain on the program, as the old pharmacy is unlikely to provide a positive reference to assist the service user to 3
4 locate another dispensing pharmacy (Ritter and Chalmers 2009:20) and especially in the face of the strained resources evident with the growing number of service users per pharmacy. Also there may not be another dispenser within close proximity. There are a number of solutions to these problems which should be considered. These include providing incentives to GPs and pharmacists as well as exploring the feasibility of allowing AOD nurse practitioners to prescribe in certain cases. Further reforms could include implementing alternate means of dispensing and increasing the accessibility of take away pharmacotherapy. Research has indicated that the provision of take away pharmacotherapy increases program retention (Ritter and Chalmers 2009:35), which is analogous with a reduction in harm to the community and service user. Further means of strengthening the system could involve increasing the level of support to prescribers through improved access to pharmacotherapy specialists and/or attaching AOD case managers to pharmacotherapy services as a further support to prescribers and dispensers. Case management services could be provided in a tiered approach, with increased support depending on the level of patient complexity. This would involve having all prescribers linked with a local AOD service and, with appropriate resources, the AOD worker would support the prescriber and provide the case management functions for those patients requiring this level of intervention. Finally, with reference to rural and regional service users, consideration could be given to more accessible models of service delivery. Workforce development Given the paucity of prescribers and dispensers, there is a need to ensure the continuity of quality service provision within a climate of exponential growth in service need. This relates to recruitment and incentives for prescribers and dispensers, and also bolstering AOD service systems to have capacity to provide support. Some of the key themes which underscore the challenges facing the diverse workforces involved in the delivery of the pharmacotherapy program relate to ensuring a high quality of service in light of an increasingly complex service user profile. The increasing complexities evident in client presentations which include but are not limited to comorbidity and poly drug use (including a substantial increase in misuse of pharmaceuticals (Ritter and Chalmers 2009:42)) on top of the difficulties in navigating an increasingly overburdened and stretched sector must be considered. The workforce, ranging from prescribers and dispensers to addiction specialists should be provided with enhanced opportunities for training and support mechanisms (such as clinical attachments) to ensure that they can meet the demands of this increasingly complex client base. In particular, there are only a limited number of AOD specialists supporting a large number of patients; there is a need to incentivise the medical sector to increase the number of AOD specialists. Ritter and Chalmers (2009:58) note that GPs are willing to take on patients presenting with complex and long term issues (such as mental illness and diabetes) and attributes their willingness, in part, to the availability of expert support. Access to addiction specialists must be resourced in a similar manner. Incentivising the pharmacotherapy workforce (as has occurred in NSW with some success (Ritter and Chalmers 2009:57)) is an important means of sustaining this workforce, as is providing expert advice, support and assistance when presented with complex cases. 4
5 Evidence indicates that the provision of counselling and psychosocial support can improve client outcomes, as long as the provision of this support is voluntary in nature (Ritter and Chalmers 2009:40). Further, the provision of voluntary counselling and support can assist those service users who wish to reduce or transit out of the pharmacotherapy system. Research must be undertaken to ensure that the Victorian pharmacotherapy program has programs and processes which will enable service users to voluntarily exit the system. This will include providing the workforce with appropriate training to facilitate this end. Thus accessibility to appropriately trained and resourced allied health staff should be prioritised. There is a need to provide the resources and infrastructure to enable collaboration between related sectors. An integrated approach to service delivery would enable a seamless referral process to other sectors as required by the service user. This requires strengthening relations, delivering training and importantly the creation of robust and transparent systems. Health and community services external to the AOD treatment sector can impact upon the long term efficacy of pharmacotherapy, including creating environments where there is a reduced likelihood of relapse. For instance, the provision of a portable model of pharmacotherapy which could attend to areas of high demand would reduce service user travel time and expense, which would increase the likelihood of service user retention and therefore reduce the risk of harm. Finally, the provision and resourcing of services which provide for other medical needs is crucial. Equity and cost There are some regions in Victoria where access to pharmacotherapy is greater than others. Moreover, rural and regional service users may be greatly disadvantaged for access related reasons noted earlier. Equity ties into quality of life and capacity to participate in community life which may be adversely impacted upon for some service users, due to system limitations with pharmacotherapy. Finally, dispensing costs may be prohibitive for some service users. As has been illustrated above, there is a skewed distribution of prescribers and dispensers across Victoria, with some regions having more than others. This is not a sustainable for the long term and creates significant disadvantage for pharmacotherapy service users in those regions without these services, or where the limited services available charge high dispensing fees (Ritter and Chalmers 2009:28). Further challenges facing pharmacotherapy service users are the prohibitive dispensing fees. This cost can be a decisive factor on pharmacotherapy service users with limited means, such as those on low income or Centrelink benefits. These fees mount on top of daily travel and living expenses. Many service users on low income or Centrelink benefits will prioritise accessing their pharmacotherapy over food, rent and other basic and essential needs (Ritter and Chalmers 2009:19). Removing dispensing fees would result in a financial burden for dispensers and would therefore likely reduce the number of dispensers, creating further service gaps. However, there are a number of proposals which were included in the Pharmacotherapy Review which should be considered, which involve the Victorian Government covering the cost of these fees or lobbying the Commonwealth to include dispensing fees on the PBS (King, Ritter and Berends 2011:25). 5
6 In order to better engage with the diverse range of pharmacotherapy clients and provide them with optimal service there is a need to ensure that services are best suited to their needs. On the ground, this translates into specialist pharmacotherapy services both to support prescribers as well pharmacotherapy service users with higher needs, as well as general prescriber and dispensing services, strategically located in regions of high demand or where there are regions with an absence of service. Currently, there are only four specialist pharmacotherapy services in Victoria, all of which are located in urban areas. New specialist pharmacotherapy services must be resourced to have capacity to respond to the broad range of complexities evident with presenting clients. Finally, there is a need to ensure that the services are tailored to changing demand. This relates to changing demographics and how Victoria s pharmacotherapy participation statistics in part vary from the national trends. For instance it is evident that there is an increase of younger service users (aged 34 years and younger) and modest decrease in older service users which is contrary to the national trends (see AIHW 2011:35 (table A4) and AIHW 2010:35 (table A5)). Figure 1 below highlights the number of pharmacotherapy service users from each age group with reference to the AIHW statistics from both the 2010 and 2011 data collection reports. Figure 1 NUMBER of pharmacotherapy service users < > AGE of service users Further research must be undertaken to map these diverse trends and ensure that programmatic activity matches contemporary community need. 6
7 VAADA s Recommendations Reform of the Victorian pharmacotherapy system is an urgent priority. The following recommendations require expeditious implementation: 1. The Victorian Government reform the pharmacotherapy system in order to cater for the growing demand; 2. The Victorian Government commit to implement those findings from the Victorian Pharmacotherapy Review which improve the range of systemic and capacity issues besetting the Victorian system. 3. The Victorian Government commission research and pilot alternative pharmacotherapy models in addition to the current GP prescriber model, including options for training additional nurse practitioners to prescribe. 4. The Victorian Government undertake research to identify effective means of assisting pharmacotherapy participants who voluntarily elect to exit the program. Pharmacotherapy participants should not be compelled to exit the program but should be provided with the means to do so if requested. 5. The Victorian Government develop strategies to increase access to take away pharmacotherapy while minimising the risk for diversion. 6. The Victorian Government develop strategies to improve access for pharmacotherapy participants who reside in rural and regional areas; this may include a mobile outreach service. 7. The Victorian Government strengthen the pharmacotherapy workforce through the provision of: o Incentives to GPs and pharmacists to respectively prescribe and dispense; o Training to prescribers; o Better access to addiction medicine specialists for prescribers; and o Enhanced psycho social services when requested by pharmacotherapy participants. 8. Pharmacotherapy training for prescribers should include attending a clinic as well as the provision of mentoring. 9. The Victorian Government plan the deployment of more specialist services, especially dispensing specialist services, and greater usage of community health services and district hospitals to meet the needs of communities in growth areas and in regional Victoria. 10. The Victorian Government subsidise dispensing fees for low income earners (ie. those on a health care card) directly or commit to work with the Commonwealth Government to amend the PBS to include methadone, buprenorphine and buprenorphine/naloxone combinations alongside other medications in Section 85 of the National Health Act The Victorian Government undertaken further research to map Victorian demographic trends to ensure that programmatic activity matches contemporary community need. Victorian Alcohol & Drug Association 211 Victoria Parade Collingwood 3066 Victoria Australia P: F: info@vaada.org.au 7
8 References AIHW 2011, National Opioid Pharmacotherapy Statistics Annual Data collection: 2010 report, Drug treatment series no. 12, Cat. no. HSE 109, Australian Institute of Health and Welfare, Canberra. AIHW 2010, National Opioid Pharmacotherapy Statistics Annual Data collection: 2009 report, Bulletin 79, Australian Institute of Health and Welfare, Canberra. Chalmers J, Ritter A, Heffernan M and McDonnell G 2009, Modelling pharmacotherapy maintenance in Australia, Research Paper no. 19, Australian National Council on Drugs, viewed 17 May Department of Health (Victoria) 2006, Policy for Maintenance Pharmacotherapy for Opioid Dependence, Melbourne. King T, Ritter A and Berends L (2011). Victorian Pharmacotherapy Review, Sydney: National Drug and Alcohol Research Centre. McDonough, M 2011, Pharmacotherapy in Victoria: From Policy to Practise, VAADA Conference 2011, viewed 17 May %20Pharmacotherapy%20in%20Victoria.pdf Victorian Alcohol and Drug Association (VAADA) Position Paper: Pharmacotherapy Ritter, A and Chalmers J 2009, Polygon: the many sides to the Australian opioid pharmacotherapy maintenance system, Research Paper no. 18, Australian National Council on Drugs, viewed 17 May Rowe J. 2004, A Raw Deal? Impact on the health consumers relative to the cost of pharmacotherapy, Salvation Army, Victoria. WHO 2011, WHO Essential Medicines Library: Methadone, viewed 20 June WHO, UN Office of Drugs and Crime and UNAIDS 2004, substitution maintenance therapy in the management of opioid dependence and HIV/AIDS prevention, World Health Organisation, United Nations Office on Drugs and Crime, Joint United Nations Programme on HIV/AIDs, viewed 24 May aids/position%20paper%20sub.%20maint.%20therapy.pdf Disclaimer While efforts have been made to incorporate and represent the views of our member agencies, the position and recommendations presented in this Paper are those of VAADA. 8
Primary Health Networks
Primary Health Networks Drug and Alcohol Treatment Activity Work Plan 2016-17 to 2018-19 Drug and Alcohol Treatment Budget Murray PHN When submitting this Activity Work Plan 2016-2018 to the Department
More informationPrimary Health Networks
Primary Health Networks Drug and Alcohol Treatment Activity Work Plan 2016-17 to 2018-19 Drug and Alcohol Treatment Budget Gippsland When submitting this Activity Work Plan 2016-2018 to the Department
More informationESTABLISHMENT OF SUPERVISED INJECTING FACILITY IN VICTORIA SUBMITTED BY THE SALVATION ARMY
ESTABLISHMENT OF SUPERVISED INJECTING FACILITY IN VICTORIA SUBMITTED BY THE SALVATION ARMY 06 APRIL 2017 The Salvation Army, State Social Command (Victoria) Establishment of Supervised Injecting Facility
More informationPrimary Health Networks
Primary Health Networks Drug and Alcohol Treatment Activity Work Plan 2016-17 to 2018-19 Drug and Alcohol Treatment Budget Murray PHN When submitting this Activity Work Plan 2016-2018 to the Department
More informationUpdated Activity Work Plan : Drug and Alcohol Treatment NEPEAN BLUE MOUNTAINS PHN
Updated Activity Work Plan 2016-2019: Drug and Alcohol Treatment NEPEAN BLUE MOUNTAINS PHN 1 Strategic Vision for Drug and Alcohol Treatment Funding The high priority service and treatment needs identified
More informationPrimary Health Networks
Primary Health Networks Drug and Alcohol Treatment Activity Work Plan 2016-17 to 2018-19 Hunter New England & Central Coast Please note: This Activity Work Plan was developed in response to the HNECC PHN
More information2018/2019. State Budget Submission. VAADA Vision. Contact Person: Sam Biondo. VAADA Objectives
State Budget Submission 2018/2019 VAADA Vision A Victorian community in which the harms associated with drug use are reduced and general health and well being is promoted. Contact Person: Sam Biondo VAADA
More informationUpdated Activity Work Plan : Drug and Alcohol Treatment. Western NSW PHN
Updated Activity Work Plan 2016-2019: Drug and Alcohol Treatment Western NSW PHN 1 Overview This Drug and Alcohol Treatment Activity Work Plan covers the period from 1 July 2016 to 30 June 2019 and is
More informationUpdated Activity Work Plan : Drug and Alcohol Treatment
Updated Activity Work Plan 2016-2019: Drug and Alcohol Treatment This Drug and Alcohol Treatment Activity Work Plan template has the following parts: 1. The updated strategic vision of each PHN, specific
More informationPrimary Health Networks
Primary Health Networks Drug and Alcohol Treatment Activity Work Plan 2016-17 to 2018-19 South Eastern Melbourne PHN When submitting this Activity Work Plan 2016-2018 to the Department of Health, the PHN
More informationCABINET PROCURING A SUBSTANCE MISUSE & COMMUNITY TREATMENT SERVICE IN RUTLAND
CABINET Report No: 105/2017 PUBLIC REPORT 16 May 2017 PROCURING A SUBSTANCE MISUSE & COMMUNITY TREATMENT SERVICE IN RUTLAND Report of the Director of Public Health Strategic Aim: Safeguarding Key Decision:
More informationChanges to Australian Government Hearing Services Program and Voucher scheme
Changes to Australian Government Hearing Services Program and Voucher scheme The Commonwealth Department of Health has published a report on its investigation into the future of the Hearing Services Program,
More informationMartin Foley, Minister for Mental Health Message to the mental health sector
Martin Foley, Minister for Mental Health Message to the mental health sector June 2015 There is a lot happening in mental health and wellbeing policy at both state and Commonwealth levels. The Andrews
More informationThe elements of cancer and palliative care reform in Victoria
The elements of cancer and palliative care reform in Victoria Dr Chris Brook Executive Director Rural and Regional Health and Aged Care Services Department of Human Services 1 Overview Rural and regional
More informationCity of Moonee Valley Draft MV 2040 Strategy
+ City of Moonee Valley Draft MV 2040 Strategy Your neighbourhood, your vision May 2018 Contact: Louise Sadler (Acting)Director of Strategy, Advocacy and Community Engagement Women s Health West 317-319
More information22 April 2002 Central Australian Aboriginal Congress Submission: Taskforce on Illicit Drugs
22 April 2002 Central Australian Aboriginal Congress Submission: Taskforce on Illicit Drugs Congress accepts the following definition: DRUG: a substance that produces a psychoactive effect. Includes alcohol,
More informationPrimary Health Networks Drug and Alcohol Treatment Services Funding. Updated Activity Work Plan : Drug and Alcohol Treatment
Primary Health Networks Drug and Alcohol Treatment Services Funding Updated Activity Work Plan 2016-2019: Drug and Alcohol Treatment Adelaide PHN This Activity Work Plan is an update to the 2016-18 Activity
More informationMoving Towards a Continuum of Services. Plumas County Alcohol & Drug Strategic Planning Process DRAFT PLAN
Moving Towards a Continuum of Services Plumas County Alcohol & Drug Strategic Planning Process DRAFT PLAN Summary Substance use, abuse and addiction range in intensity from experimentation to severe and
More informationImproving access to dental care in rural and remote Australia
ABN: 68 480 848 412 National Rural Health Conference PO Box 280 Deakin West ACT 2600 Australian Journal of Rural Health Phone: (02) 6285 4660 Fax: (02) 6285 4670 Web: www.ruralhealth.org.au Email: nrha@ruralhealth.org.au
More informationUpdated Activity Work Plan : Drug and Alcohol Treatment
Web Version HPRM DOC/17/1043 Updated Activity Work Plan 2016-2019: Drug and Alcohol Treatment This Drug and Alcohol Treatment Activity Work Plan template has the following parts: 1. The updated strategic
More informationHARM REDUCTION AUSTRALIA OPIOID TREATMENT PROGRAM FORUM: NSW
HARM REDUCTION AUSTRALIA OPIOID TREATMENT PROGRAM FORUM: NSW NOVEMBER 2017 Introduction The Opioid Treatment Program (OTP) is one of the most rigorously evaluated and proven treatments available in the
More informationCommunity alcohol detoxification in primary care
Community alcohol detoxification in primary care 1. Purpose The purpose of this primary care enhanced service is to improve the health and quality of life of people whose health may be compromised by their
More informationThe Aboriginal Maternal and Infant Health Service: a decade of achievement in the health of women and babies in NSW
The Aboriginal Maternal and Infant Health Service: a decade of achievement in the health of women and babies in NSW Elisabeth Murphy A,B and Elizabeth Best A A Maternity, Children and Young People s Health
More informationSUPPORTING AND PROMOTING THE PROVISION OF MTOP IN VICTORIA, AUSTRALIA.
SUPPORTING AND PROMOTING THE PROVISION OF MTOP IN VICTORIA, AUSTRALIA. ANNARELLA HARDIMAN PREGNANCY ADVISORY SERVICE, THE ROYAL WOMEN S HOSPITAL AUTHORS: ANNARELLA HARDIMAN AND DR. PADDY MOORE 1; KYLIE
More informationSeptember Contact John Rogerson Chief Executive Officer Alcohol and Drug Foundation Executive Summary adf.org.
AN EXECUTIVE SUMMARY OF EVIDENCE PUT TO THE INQUIRY INTO THE DRUGS, POISONS AND CONTROLLED SUBSTANCES AMENDMENT (PILOT MEDICALLY SUPERVISED INJECTING CENTRE BILL) 2017 September 2017 Contact John Rogerson
More informationEliminating Viral Hepatitis in Australia: Where are we in 2017?
This document was prepared by Hepatitis Australia in consultation with a variety of stakeholders working in the areas of hepatitis B and hepatitis C in Australia. This included people involved in primary
More informationSTRADA
The sense of STRADA STRADA STRADA is Scotland s leading workforce development organisation in the field of substance misuse. We make a significant contribution to the workforce development of those employed
More informationVictorian Parliamentary Inquiry into the Drugs, Poisons and Controlled Substances Amendment (Pilot Medically Supervised Injecting Centre) Bill 2017
Victorian Parliamentary Inquiry into the Drugs, Poisons and Controlled Substances Amendment (Pilot Medically Supervised Injecting Centre) Bill 2017 19 April 2017 That the Government: VHA Recommendations
More informationVolunteering in NHSScotland Developing and Sustaining Volunteering in NHSScotland
NG11-07 ing in NHSScotland Developing and Sustaining ing in NHSScotland Outcomes The National Group for ing in NHS Scotland agreed the outcomes below which formed the basis of the programme to develop
More informationPosition is based Access Health & Community: Hawthorn and Doncaster East Manager, Alcohol and Other Drug Service
Position Details Position Title Mode of Employment Award/EBA Classification Salary Packaging Department/Team Location Reports to Direct Reports Probationary Period Working with Children Check required
More informationDeveloping targeted treatment responses to methamphetamine dependence
Developing targeted treatment responses to methamphetamine dependence Briefing Paper by UnitingCare ReGen March 2015 Executive summary: UnitingCare ReGen s (ReGen) purpose is to reduce alcohol and other
More informationNeedle and Syringe Programs - 17 October 2013
Needle and Syringe Programs - 17 October 2013 ANCD Position Paper: Needle and Syringe Programs MEDIA RELEASE 17 October 2013 The Australian National Council on Drugs (ANCD) has today released a position
More informationNational Guidelines. Interim methadone prescribing
National Guidelines Interim methadone prescribing 2007 National Guidelines Interim methadone prescribing Citation: Ministry of Health. 2007. National Guidelines: Interim methadone prescribing. Wellington:
More informationNorth Coast Primary Health Network Drug and Alcohol Treatment Updated Activity Work Plan
North Coast Primary Health Network Drug and Alcohol Treatment Updated Activity Work Plan 2016-2019 Contents Overview... 3 Strategic Vision for Drug and Alcohol Treatment... 3 Planned activities: Drug and
More informationReview of Controlled Drugs and Substances Act
Review of Controlled Drugs and Substances Act Canadian Medical Association: Submission to Health Canada in response to the consultation on the Controlled Drugs and Substances Act and its regulations A
More informationService Level Agreement for the Provision of Level 1 Substance Misuse Services from a Community Pharmacy under contract to NHS Grampian
Service Level Agreement for the Provision of Level 1 Substance Misuse Services from a Community Pharmacy under contract to NHS Grampian 1. Introduction The provision of Substance Misuse (SM) services through
More informationLooking back to look forward
January 2018 In this issue 2 Sector update December 2017 3 Specialist Family Violence Advisor Capacity Building Program. In a Nutshell 4 Real Time Prescription Monitoring and AOD treatment 5 state budget
More informationSubstance use and misuse
An open learning programme for pharmacists and pharmacy technicians Substance use and misuse Educational solutions for the NHS pharmacy workforce DLP 160 Contents iii About CPPE open learning programmes
More informationHARM REDUCTION AUSTRALIA OPIOID TREATMENT PROGRAM FORUM: QUEENSLAND
HARM REDUCTION AUSTRALIA OPIOID TREATMENT PROGRAM FORUM: QUEENSLAND OCTOBER 2017 Introduction The Opioid Treatment Program (OTP) is one of the most rigorously evaluated and proven treatments available
More informationThe Cancer Council NSW. Submission to the Legislative Assembly Public Accounts Committee. Inquiry into NSW State Plan Reporting
The Cancer Council NSW Submission to the Legislative Assembly Public Accounts Committee Inquiry into NSW State Plan Reporting December 2007 2 Inquiry into NSW State Plan Reporting The Cancer Council NSW
More informationA long-term plan for mental health
A long-term plan for mental health The Plan to rebuild The Plan to rebuild A long-term plan for mental health Tasmania s mental health system has become complex, disjointed and confusing to navigate. There
More informationThree years of transition
Three years of transition The Homelessness Transition Fund 2011 to 2014 Evaluation summary 1 Transition in numbers 1 st round 2 nd round 20m in grants 3 rd Future Ready Fund 2014 round round 2011 175 projects
More informationImplementation plan for the systems approach to suicide prevention in NSW
Implementation plan for the systems approach to suicide prevention in NSW Summary paper October 2015 Putting health in mind IMPLEMENTATION PLAN FOR THE SYSTEMS APPROACH TO SUICIDE PREVENTION IN NSW Rationale
More informationIntegrating ITEP BETI across services
Integrating ITEP BETI across services Luke Mitcheson, Clinical Team, National Treatment Agency Optimising i i Treatment t Effectiveness, KCA, London 30th November 2009 Structure What is ITEP / BTEI? Why
More informationThe Silent Disease Inquiry into Hepatitis C in Australia
Australian Government response to the House of Representatives Standing Committee on Health report: The Silent Disease Inquiry into Hepatitis C in Australia November 2016 LIST OF ABBREVIATIONS AHPPC Australian
More informationRecommendation 2: Voluntary groups should be supported to build their capacity to promote mental health among their client groups.
Submission to the independent review group examining the role of voluntary organisations in the operation of health and personal social services in Ireland May 2018 Introduction Mental Health Reform (MHR)
More informationSTATEMENT. of the. American Medical Association. for the Record. House Committee on Energy and Commerce
STATEMENT of the American Medical Association for the Record House Committee on Energy and Commerce RE: Federal Efforts to Combat the Opioid Crisis: A Status Update on CARA and Other Initiatives October
More informationHHSC LAR Request. Substance Abuse Disorder Coalition. Contact Person: Will Francis Members:
HHSC LAR Request Substance Abuse Disorder Coalition Contact Person: Will Francis wfrancis.naswtx@socialworkers.org Members: NAMI Texas Children s Defense Fund Texas Communities for Recovery National Association
More informationNew South Wales Needle and Syringe Program Enhanced Data Collection
New South Wales Needle and Syringe Program Enhanced Data Collection 2017 A report for the NSW Ministry of Health by the Kirby Institute, UNSW Australia August 2017 Prepared by Ms Louise Geddes, Dr Jenny
More informationINNOVATIVE DATA TO INFORM POLICY PLANNING AND INTERVENTION
INNOVATIVE DATA TO INFORM POLICY PLANNING AND INTERVENTION Authors: Lloyd B 1,2, Killian J 2, Gao CX 2, Barker SF 2, Matthews S 2, Heilbronn C 2 1 Monash University, 2 Turning Point Nominated Chair: Lloyd
More information4.0 Current Service Configuration
4.0 Current Service Configuration Adult addictions services are delegated to the Edinburgh Integration Joint Board (IJB) and the responsibility for planning and developing these services sits with the
More informationPrimary Health Networks
Primary Health Networks Activity Work Plan 2016-17 to 2018-19 Budget Central and Eastern Sydney PHN When submitting this Activity Work Plan 2016-2018 to the Department of Health, the PHN must ensure that
More informationBuilding a New Approach to Health Care Services for Hard to Reach Clients
Building a New Approach to Health Care Services for Hard to Reach Clients Community Discussion and Open House January 30, 2013 Fernwood Community Association 1923 Fernwood Street February 6, 2013 North
More informationTo improve the current Strategy, Shelter WA recommends the City of Rockingham:
Executive Summary Shelter WA welcomes the opportunity to provide a submission to the City of Rockingham s Draft Community Support Services Strategy 2017-2022. Shelter WA is an independent, community based
More information>Hepatitis NSW will continue to
Continued Equal Treatment Access to hepatitis C medicines KURT SAYS Everyone with viral hepatitis deserves equal access to treatment. Thankfully Australians can access hepatitis C treatment before they
More informationTapping the Potential of Pharmacists in Primary Care Services
Tapping the Potential of Pharmacists in Primary Care Services A/Prof Timothy F Chen President, Social & Administrative Pharmacy Section, FIP 22 nd -24 th April 2015 The University of Sydney Page 1 The
More informationTHREE STEPS TO CHANGE LIVES. How we can act effectively to reduce suicide in Ireland
THREE STEPS TO CHANGE LIVES How we can act effectively to reduce suicide in Ireland THREE STEPS TO CHANGE LIVES HOW WE CAN ACT EFFECTIVELY TO REDUCE SUICIDE IN IRELAND More than 450 people die by suicide
More informationPH52. Audit tool for the implementation of. NICE public health guidance 52 Needle and syringe programmes
PH52 Audit tool for the implementation of NICE public health guidance 52 Needle and syringe programmes Introduction This audit tool has been developed to help you audit implementation of, and compliance
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Methadone and buprenorphine for the management of opioid dependence
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Appraisal Methadone and buprenorphine for the management of opioid dependence Comments received from Consultees and Commentators on the draft scope
More informationUpdated Activity Work Plan : Drug and Alcohol Treatment
Updated Activity Work Plan 2016-2019: Drug and Alcohol Treatment This Drug and Alcohol Treatment Activity Work Plan template has the following parts: 1. The updated strategic vision of each PHN, specific
More informationPrimary Health Networks
Primary Health Networks Drug and Alcohol Treatment Activity Work Plan 2016-17 to 2018-19 Adelaide PHN This template was used to submit the Primary Health Network s (PHN s) Activity Work Plans to the Department
More informationHertfordshire Young People s Substance Misuse Strategic Plan
Hertfordshire Young People s Substance Misuse Strategic Plan 2014 15 1 1. Introduction and context Young people misusing substances can cause harm to our communities through crime and antisocial behaviour,
More informationCOVER SHEET. Accessed from Copyright 2003 Australasian Medical Publishing Company
COVER SHEET Cairns, Will and Yates, Patsy (2003) Education and training in palliative care. Medical Journal of Australia 179:S26-S28. - reproduced with permission. Accessed from http://eprints.qut.edu.au
More informationPalliative Care & Private Health Insurance
Palliative Care & Private Health Insurance Focus of Presentation 1. Legislation 2. Early Review of Changes 3. Trends in Palliative Care Mandatory Coverage Coverage by Insurers 4. MBS & Palliative Care
More informationPsychiatric Disability Rehabilitation and Support Services Reform Framework
Psychiatric Disability Rehabilitation and Support Services Reform Framework Mental Health Reform Strategy Mental Health, Drugs and Regions Division Department of Health Level 17, 50 Lonsdale Street Melbourne
More informationHepatitis C Strategy. About us. What is hepatitis C?
Hepatitis C Strategy About us We support people to take control of their lives and make positive changes. For fifty years we have made a difference to people who want to change their relationship with
More informationDUMFRIES AND GALLOWAY ALCOHOL AND DRUG PARTNERSHIP; PRIORITY ACTIONS AND
DUMFRIES AND GALLOWAY ALCOHOL AND DRUG PARTNERSHIP; PRIORITY ACTIONS 2013-14 AND 2014-15 RECOMMENDATION/WORKPLAN CURRENT POSITION IN D & G PLAN 1. Annual Report 1.1 Develop robust reporting mechanisms
More informationReferral to the Women s Alcohol and Drug Service (WADS) Procedure
Procedure Referral to the Women s Alcohol and Drug Service (WADS) Procedure. Purpose The following document describes criteria for the referral to Women s Alcohol and Drug Service (WADS) and how a referral
More informationArts therapy changes to systems through alternative health and wellness program
POSTER 22 Arts therapy changes to systems through alternative health and wellness program Jennifer Stirling 1 1 Maryborough District Health Services, Vic Introduction Maryborough District Health Service
More informationSubmission to: Responding to the Problem of Recidivist Drink Drivers
Submission to: Responding to the Problem of Recidivist Drink Drivers It is our belief that Tasmanian community sector organisations contribute effectively to addressing this problem in the community and
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Drug Misuse: opiate detoxification of drug misusers in the community, hospital and prison. 1.1 Short title Drug misuse detoxification
More informationCompass. Research to policy and practice. Issue 03 May Ms Mary Stathopoulos, Senior Research Officer, Australian Institute of Family Studies.
Compass Research to policy and practice Issue 03 May 2016 Establishing the Connection: Interventions linking service responses for sexual assault with drug or alcohol use/abuse: Key findings and future
More informationVictim-centric Policing
Slide 1 Victim-centric Policing Providing an effective and responsive service to individuals and communities impacted by crime and victimisation (Introduce content) Slide 2 Overview Today s presentation
More informationINDIGENOUS MALE HEALTH
INDIGENOUS MALE HEALTH A report for Indigenous males, their families and communities, and those committed to improving Indigenous male health Dr Mark Wenitong Executive Officer, Australian Indigenous Doctors
More informationCONTENTS. Page. An Introduction The Whitechapel Centre 3-8. Our Services Our Impact Our Policies:
CONTENTS Page An Introduction The Whitechapel Centre 3-8 Our Services 9-11 Our Impact 12-13 Our Policies: Information Systems Policy including social media 14 Smoking Policy 28 Health & Safety Policy 31
More informationOur mission: High impact support Without judgement Fullstop. Our values: Social Justice Inclusion Empowerment Integrity Respect Courage Commitment
Position Title Portfolio Department Reports to: Award: Employment type: Location: No. direct reports Hiring Leader Client Engagement Officer Community Health The Living Room Clinical Team Leader SCHaHDS
More informationSUBMISSION FROM THE NATIONAL AUTISTIC SOCIETY SCOTLAND
SUBMISSION FROM THE NATIONAL AUTISTIC SOCIETY SCOTLAND 1. The National Autistic Society (Scotland) is part of the UK s leading charity for people affected by autism 1. Founded in 1962, by a group of parents
More informationSenior Clinician Early Intervention Youth Psychosis. DATE: May 2017 ORGANISATIONAL ENVIRONMENT
POSITION: REPORTS TO: LOCATED: Senior Clinician Early Intervention Youth Psychosis Senior Manager Melbourne CBD DATE: May 2017 ORGANISATIONAL ENVIRONMENT Melbourne City Mission is a leader and innovator
More informationThe next steps
Greater Manchester Hepatitis C Strategy The next steps 2010-2013 Endorsed by GM Director of Public Health group January 2011 Hepatitis Greater Manchester Hepatitis C Strategy 1. Introduction The Greater
More informationOUTCOMES OF TRAINING GENERAL PRACTITIONERS TO PRESCRIBE METHADONE
LIBBY HOTHAM, ANN M ROCHE, EMMA FITZGERALD OUTCOMES OF TRAINING GENERAL PRACTITIONERS TO PRESCRIBE METHADONE LIBBY HOTHAM, ANN M ROCHE, EMMA FITZGERALD Over the last decade, most jurisdictions throughout
More informationPragmatic and Creative Responses to the Opioid Crisis in Connecticut
Focusing on Highly Vulnerable Populations Track Pragmatic and Creative Responses to the Opioid Crisis in Connecticut A special thanks to our presenting sponsor: Presenters: Shawn Lang Deputy Director AIDS
More informationE. A Public Health Oriented Palliative Care System in Australia
E. A Public Health Oriented Palliative Care System in Australia Overview Similar to other developed countries, Australia s population is ageing and there is increasing demand for equitable access to high
More informationThe role of cancer networks in the new NHS
The role of cancer networks in the new NHS October 2012 UK Office, 89 Albert Embankment, London SE1 7UQ Questions about cancer? Call the Macmillan Support Line free on 0808 808 00 00 or visit macmillan.org.uk
More informationWhat is harm reduction?
What is harm reduction? The International Harm Reduction Association (IHRA) defines harm reduction as the policies, programmes and practices that aim to reduce the harms associated with the use of psychoactive
More informationbulletin criminal justice Police drug diversion in Australia Key Points Jennifer Ogilvie and Katie Willis
criminal justice bulletin Police drug diversion in Australia Key Points Jennifer Ogilvie and Katie Willis Diversion involves the redirection of offenders away from conventional criminal justice processes.
More informationSubmitted to the House Energy and Commerce Committee. Federal Efforts to Combat the Opioid Crisis
STATEMENT FOR THE RECORD Submitted to the House Energy and Commerce Committee Federal Efforts to Combat the Opioid Crisis October 25, 2017 America s Health Insurance Plans 601 Pennsylvania Avenue, NW Suite
More informationPart of the Continuum of Care. Harm Reduction. Gino Vumbaca President Harm Reduction Australia
Part of the Continuum of Care Harm Reduction Gino Vumbaca President Harm Reduction Australia What is Harm Reduction The defining features are the focus on the reduction of harm, rather than on the prevention
More informationDrug Misuse and Dependence Guidelines on Clinical Management
Department of Health Scottish Office Department of Health Welsh Office Department of Health and Social Services, Northern Ireland Drug Misuse and Dependence Guidelines on Clinical Management An Executive
More informationTajikistan National Report. Summary HARM REDUCTION WORKS FUND IT! Arguments for strategic investment. Summary of National Report: Tajikistan
HARM REDUCTION WORKS FUND IT! National Report Summary Arguments for strategic investment With the support of The present document contains a summary of the key conclusions and recommendations provided
More informationThe science of the mind: investigating mental health Treating addiction
The science of the mind: investigating mental health Treating addiction : is a Consultant Addiction Psychiatrist. She works in a drug and alcohol clinic which treats clients from an area of London with
More informationGuidelines For Services Providing Injecting Equipment
Guidelines For Services Providing Injecting Equipment Best Practice Recommendations For Commissioners and Injecting Equipment Provision (IEP) Services in Scotland (Scottish Government 2010) January 2014
More informationRDAA 2016 ELECTION PLATFORM RECOMMENDATIONS TO THE PARTIES
RURAL DOCTORS ASSOCIATION OF AUSTRALIA RDAA 2016 ELECTION PLATFORM RECOMMENDATIONS TO THE PARTIES INTRODUCTION The Rural Doctors Association of Australia (RDAA) is the peak national body representing the
More informationNCACH RAPID CYCLE APPLICATION: OPIOID PROJECT North Central Accountable Community of Health - Medicaid Transformation Project
NCACH RAPID CYCLE APPLICATION: OPIOID PROJECT North Central Accountable Community of Health - Introduction The North Central Accountable Community of Health (NCACH) is accepting applications from partners
More informationVictorian AIDS Council Gay Men s Health Centre
Victorian AIDS Council Gay Men s Health Centre including the Positive Living Centre VAC Reg. No. A 3609 GMHC Reg No. A0010550F VAC ABN 52 907 644 835 GMHC ABN 87 652 472 253 AUSTRALIAN GOVERNMENT DEPARTMENT
More informationQUARTERLY PROVIDER MEETING MARCH 9, 2017 SUZANNE BORYS, ED.D.
2017 State Targeted Response to the Opioid Crisis Grants QUARTERLY PROVIDER MEETING MARCH 9, 2017 SUZANNE BORYS, ED.D. H.R.6-21st Century Cures Act The 21st Century Cures Act is a United States law enacted
More informationGavi Risk Appetite Statement Version 2.0
Gavi Risk Appetite Statement Version 2.0 DOCUMENT ADMINISTRATION VERSION NUMBER 1.0 2.0 APPROVAL PROCESS Reviewed and recommended by: Gavi Programme & Policy Committee Reviewed and approved by: Gavi, the
More informationMOVEMBER FUNDED MEN S HEALTH INFORMATION RESOURCES EVALUATION BRIEF. 1 P age
MOVEMBER FUNDED MEN S HEALTH INFORMATION RESOURCES EVALUATION BRIEF 1 P age Contents 1. Purpose... 3 2. Background... 3 3. beyondblue, the national depression and anxiety initiative... 4 4. Movember funded
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Drug Misuse: opiate detoxification of drug misusers in the community, hospital and prison. 1.1 Short title Drug misuse detoxification
More informationKent Joint Commissioning Action Plan For Adults with Autism and or ADHD (2017 / 2021)
Easy Read Kent Joint Commissioning Action Plan For Adults with Autism and or ADHD (2017 / 2021) Action Plan The plan was developed to address the needs identified from the Kent Autism Strategy and Joint
More informationOpioid Substitution Treatment in Christchurch
Opioid Substitution Treatment in Christchurch Of CORS you can do it Leadership Day 20 November 2014 Dr Carmen Lowe, Clinical Head, Consultant Psychiatrist and Addiction Specialist Kaye Johnston Service
More information